GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. The two posters will highlight preclinical data on tri-specific NK cell engagers for the treatment of mesothelioma and prostate cancer.
Poster Presentations
Title: Tri-specific killer engagers target natural killer cells towards mesothelioma
Abstract Number: 1202
Presenter: Pippa Kennedy and Martin Felices
Date: November 11, 2022
Location and time: Poster Hall from 9:00am – 8:30pm ET
Title: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA)
Abstract Number: 1204
Presenter: Shee Kwan Phung and Martin Felices
Date: November 11, 2022
Location and time: Poster Hall from 9:00am – 8:30pm ET
Original source can be found here.